The wobbly status of ketolides: Where do we stand?

Expert Opinion on Investigational Drugs

Volumn 23, Issue 10, 2014, Pages 1313-1319

  Georgopapadakou, Nafsika H ^a  

^a Independent Research Consultant   (United States)

Author keywords

Cethromycin; Chlamydia pneumoniae; Chlamydophila pneumoniae; Community acquired pneumonia; Cost benefit; Haemophilus; Hepatotoxicity; Ketek; Ketolides; Legionella; Macrolides; Methicillin resistant Staphylococcus aureus; Modithromycin; Moraxella; Mycobacterium; Solithromycin; Streptococcus; Telithromycin

Indexed keywords

BETA LACTAM DERIVATIVE; CETHROMYCIN; CLARITHROMYCIN; KETOLIDE; MACROLIDE; MODITHROMYCIN; OXAZOLIDINONE DERIVATIVE; QUINOLONE DERIVATIVE; SOLITHROMYCIN; TELITHROMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG MECHANISM; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOMODULATION; LEGIONELLA PNEUMOPHILA; LIVER TOXICITY; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TISSUE DISTRIBUTION; VOMITING; BACTERIA; CHEMISTRY; COMMUNITY-ACQUIRED INFECTIONS; DRUG APPROVAL; DRUG DESIGN; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; DRUG-INDUCED LIVER INJURY; HUMANS; KETOLIDES; PNEUMONIA, BACTERIAL;

EID: 84907050377     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.954036     Document Type: Review

References (62)

1. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 2009;360:439-43
2. Georgopapadakou NH. Prospects for new antibacterials: can we do better? Expert Opin Investig Drugs 2014;23:145-8
3. Watkins RR, Bonomo RA. Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis. Expert Rev Anti Infect Ther 2013;11:543-5
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72
5. Liang J-H, Han X. Structure-activity relationships and mechanism of action of macrolides derived from erythromycin as antibacterial agents. Curr Top Med Chem 2013;13:3131-64
6. Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002;62:1771-804
7. Kirst HA. New macrolide, lincosaminide and streptogramin B antibiotics. Expert Opin Ther Pat 2010;20:1343-57
8. Pavlović D, Fajdetić A, Mutak S. Novel hybrids of 15-membered 8a-and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. Bioorg Med Chem 2010;18:8566-82
9. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999;31:623-31
10. Wilson DN, Harms JM, Nierhaus KH, et al. Species-specific antibiotic-ribosome interactions: implications for drug development. Biol Chem 2005;386:1239-52
11. Zuckerman JM, Qamar F, Bono BR. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am 2009;23:997-1026
12. McCuster KP, Fujimori DG. The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance. ACS Chem Biol 2012;7:64-72
13. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-23
14. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-4
15. Soreth J, Cox E, Kweder S, et al. Ketek-the FDA perspective. N Engl J Med 2007;356:1675-6
16. Young D. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning. Am J Health Syst Pharm 2007;64:124-5
17. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
18. Rafie S, MacDougall C, James CL. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 2010;30:290-303
19. Revill P, Bolós J, Serradell N. EDP-420: ketolide antibiotic. Drugs Future 2006;31:479-83
20. Fernandes P, Pereira D, Jamieson B, Keedy K. Solithromycin. Macrolide antibiotic. Drugs Future 2011;36:751-8
21. Dunkle JA, Xiong L, Mankin AS, Cate JH. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc Natl Acad Sci USA 2010;107:17152-7 •• A lucid account (with excellent figures) of ketolide interactions with the PTC in Escherichia coli, vis-a-vis other antibacterials targeting that ribosomal site. Details subtle differences in drug binding between bacterial species, particularly archaea, and clearly shows ketolides' 'binding edge' against macrolide-resistant organisms.
22. Kannan K, Vazquez-Laslop N, Mankin AS. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 2012;151:508-20 •• The report provides new insights on the mechanism of macrolide action. Contrary to long-held belief, macrolides block the ribosomal tunnel only partially, allowing the synthesis of some proteins depending on their N-terminal sequence. By being protein-specific in their inhibition, macrolides reshape the cellular proteome, a finding with important implications for drug discovery.
23. Krokidis MG, Marquez V, Wilson DN, et al. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrob Agents Chemother 2014;58:472-80
24. Llano-Sotelo B, Dunkle J, Klepacki D, et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother 2010;54:4961-70
25. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). Diagn Microbiol Infect Dis 2009;63:302-8
26. Azoulay-Dupuis E, Mohler J, Bedos JP, et al. Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model. Antimicrob Agents Chemother 2006;50:3033-8
27. Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of the investigational ketolide cethromycin against macrolide-and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). J Antimicrob Chemother 2009;63:620-2
28. Sato T, Tateda K, Kimura S, et al. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob Agents Chemother 2011;55:1588-93
29. Woosley LN, Castanheira M, Jones RN. CEM-101 activity against gram-positive organisms. Antimicrob Agents Chemother 2010;54:2182-7
30. Farrell DJ, Castanheira M, Sader HS, Jones RN. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J Infect 2010;61:476-83
31. Putnam SD, Castanheira M, Moet GJ, et al. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 2010;66:393-401
32. Bebear CM, Renaudin H, Aydin MD, et al. In-vitro activity of ketolides against mycoplasmas. J Antimicrob Chemother 1997;39:669-70
33. Hammerschlag MR, Roblin PM, Bebear CM. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory pathogens. J Antimicrob Chemother 2001;48(Suppl T1):25-31
34. Doern GV. Macrolide and ketolide resistance with Streptococcus pneumoniae. Med Clin North Am 2006;90:1109-24
35. Felmingham D, Canton R, Jenkins SG. Regional trends in b-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-18
36. Hirakata Y, Mizuta Y, Wada A, Kohno S. The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4. Jpn J Infect Dis 2007;60:48-50
37. Reynolds ED, Cove JH. Resistance to telithromycin is conferred by msr(A), msrC and msr(D) in Staphylococcus aureus. J Antimicrob Chemother 2005;56:1179-80
38. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 2014;12:35-48
39. Bogdanovich T, Bozdogan B, Appelbaum PC. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. Antimicrob Agents Chemother 2006;50:893-8
40. Nikaido H, Pages JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012;36:340-63
41. Gupta P, Kannan K, Mankin A, Vazquez-Laslop N. Regulation of gene expression by macrolide-induced ribosomal frameshifting. Mol Cell 2013;52:629-42 •• Describes a novel mechanism for the induction of resistance genes by ketolides. While macrolides induce resistance via translation arrest at the upstream ORF (uORF) of resistance genes, ketolides induce resistance via frameshifting at the uORF and unfolding of the mRNA.
42. Al-Lahham A, Reinert RR Time-kill kinetics of Streptococcus pneumoniae with reduced susceptibility to telithromycin. Chemotherapy 2007;53:190-3
43. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615
44. Leiva M, Ruiz-Bravo A, Moreno E, Jimenez-Valera M. Telithromycin inhibits the production of proinflammatory mediators and the activation of NF-kB in in vitro-stimulated murine cells. FEMS Immunol Med Microbiol 2008;53:343-50
45. Lotter K, Hocherl K, Bucher M, Kees F. In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice. J Antimicrob Chemother 2006;58:615-21
46. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600
47. Zeitlinger M, Wagner CC, Heinisch B. Ketolides-the modern relatives of macrolides: the pharmacokinetic perspective. Clin Pharmacokinet 2009;48:23-38
48. Traunmüller F, Fille M, Thallinger C, Joukhadar C. Multiple-dose pharmacokinetics of telithromycin in peripheral soft tissues. Int J Antimicrob Agents 2009;34:72-5
49. Still JG, Schranz J, Degenhardt TP, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 2011;53:1997-2003
50. Nosaka H, Nadai M, Kato M, Hasegawa T. Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. Life Sci 2006;79:50-6
51. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003;57:377-84
52. Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62
53. English ML, Fredericks CE, Milanesio NA, Eiznhamer DA. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. Antimicrob Agents Chemother 2012;56:2037-47
54. Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013;57:2526-34
55. Liu C-N, Somps CJ. Telithromycin blocks neuromuscular transmission and inhibits nAChR currents in vitro. Toxicol Lett 2010;194:66-9
56. Bottenberg MM, Wall GC, Hicklin GA. Apparent anaphylactoid reaction after treatment with a single dose of telithromycin. Ann Allergy Asthma Immunol 2007;98:89-91
57. Bolesta S, Roslund BP. Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review. Am J Health Syst Pharm 2008;65:37-41
58. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006;144:415-20
59. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
60. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72
61. Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother 2008;9:267-83
62. Echols RM. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Ann N Y Acad Sci 2011;1241:153-61